Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Antiviral Res. 2016 Nov 27;137:134–140. doi: 10.1016/j.antiviral.2016.11.023

Figure 4. Therapeutic effect of sofosbuvir in mice.

Figure 4

Five week-old WT C57BL/6 mice were treated at day −1 with 2 mg of anti-Ifnar1 blocking mAb. On day 0, animals were inoculated via a subcutaneous route in the footpad with 105 FFU of mouse-adapted ZIKV Dakar. On day 1, oral therapy was initiated with ~33 mg/kg/day sofosbuvir dissolved in Kool-Aid® or Kool-Aid® vehicle control. Survival (A) and aggregate body weights (B) were recorded. Results are pooled from two independent experiments with a total of n = 10 in each group. *, P < 0.05 (log-rank test).